After weighing both arguments carefully, the bear case carries the heavier evidentiary load on five dimensions that matter most for the next 6-12 months. First, on the most recent hard data: Q2 2026 printed -47.5% EPS, -39.5% net income, and -34.5% operating income YoY. The bull anchored the "trough margins" thesis on Q1 2026 (+33% operating income) and ignored Q2 — that is selection bias, and Q2 is the more relevant data point for forward expectations. Second, on balance sheet integrity: net debt rose 6x to $27.24B, tangible book value turned negative (-$1.04B), and goodwill+intangibles now represent 48% of total assets. The bull's "zero-dilution growth bet" framing is technically true but obscures material fragility — a single goodwill impairment test failure destroys more equity value than the entire TactiFlex opportunity creates. Third, on the macro binary: with 89% probability of a Fed hike and 0% probability of cuts priced by Polymarket, the dominant variable for ABT over the next 30-60 days is hawkish, not neutral. Multiple compression is the base case, not the tail case. Fourth, on valuation dependency: the bull's 16.8x forward P/E argument is entirely contingent on consensus EPS of $6.06 holding. Consensus has been systematically wrong on ABT all year, and a Q3 print that confirms Q2's deterioration will force EPS cuts that turn 16.8x into 19-20x. The bull is buying a multiple that doesn't exist yet. Fifth, on technical structure: death cross confirmed, price below all three MAs, MACD fresh negative crossover, RSI non-divergent — five independent momentum signals align bearish. The bull's "death crosses have been buy signals" rebuttal relies on n=4 over 15 years in dissimilar macro regimes; that is anecdote, not evidence. Where the bull scores legitimate points: structural $100-105 support has historical precedent, $7.2B FCF is real, 2.44% Dividend King yield with 1.7x FCF coverage is genuine, and 0.586 beta limits downside volatility. TactiFlex Duo is a real but incremental 0.1-0.2% revenue tailwind, not a thesis-changer. The bull's risk/reward math is also flawed: from $101.95, $116 upside (+13.8%) versus $90 base-case downside (-11.7%) is closer to 1:1 than the claimed 6:1. The asymmetry the bull promised does not exist at current prices. Given the broken trend, deteriorating earnings, hostile macro, and balance sheet fragility, we lean cautious — but stop short of full Sell given the defensive characteristics (FCF generation, dividend floor, low beta) that prevent a straight-line lower scenario. Hold below benchmark weight and wait for either a confirmed basing pattern below $90 or a trend repair above $108 before reconsidering.

POSITION STRATEGY: Reduce ABT exposure to below benchmark weight. If held at benchmark weight (approximately 5% of healthcare allocation), trim to approximately 2-2.5%. If held as a general equity position, reduce position size by 30-50% from current levels. The defensive yield and FCF profile justify maintaining some exposure, but the broken trend and earnings deterioration warrant a smaller position than the benchmark would imply.

ENTRY/EXIT LEVELS: Trim zone: $100-103 — current trading range. Begin reducing exposure on any rallies into this zone; rallies into resistance at the 10 EMA ($106.81) and 200 SMA ($104.80) are selling opportunities. Hard stop at $99.50 (close below the $100.53 structural swing low) on any remaining position. A break below $100.53 confirms the bear case and triggers full exit. Re-entry trigger: Do not re-enter until EITHER (a) a confirmed basing pattern forms below $90 with a higher low and RSI divergence (target re-entry zone $85-90 if the May 2026 low of $81.98 holds on a retest), OR (b) a confirmed trend repair with a close above $108 on volume >15M shares (which would invalidate the death cross structure). A close above $108 with volume confirmation would force reassessment toward Hold/Overweight; until then, treat any rallies as distribution opportunities.

RISK MANAGEMENT: Avoid adding new exposure ahead of the September FOMC meeting (binary macro event with 82% hike probability per Polymarket). Wait at least one week post-FOMC to reassess rate trajectory before considering incremental buying. Monitor Q3 2026 earnings print closely — if Q3 confirms Q2's EPS deterioration, the forward P/E thesis collapses and further trimming is warranted.

CATALYST CALENDAR: (a) September FOMC meeting: hawkish outcome expected; position defensively. (b) Q3 2026 earnings (mid-to-late October 2026 estimate): high risk of consensus EPS cuts; prepare to reduce further on disappointment. (c) TactiFlex Duo U.S. commercial launch metrics (Q4 2026 / early 2027): track EP franchise revenue trajectory as the primary evidence on whether the share-gain thesis is real. (d) Annual goodwill impairment test (Q4 reporting): monitor for any intangibles writedown signals.

HEDGING: For holders with concentrated ABT exposure, consider protective puts at $95 strike (3-month tenor) as cheap insurance against a $90 retest while maintaining dividend income.

TIME HORIZON: This is a 6-12 month tactical underweight, not a structural call. Re-evaluate the rating at each quarterly print and on resolution of the macro binary (post-September FOMC).

The investment plan presents an overwhelming bearish case across five independent dimensions: (1) Q2 2026 earnings showed severe deterioration (-47.5% EPS, -39.5% net income, -34.5% operating income YoY), making the "trough margins" bull thesis selection-biased; (2) balance sheet fragility is material, with net debt up 6x to $27.24B and tangible book value turning negative, exposing equity to goodwill impairment risk; (3) the macro binary is hawkish (89% Fed hike probability per Polymarket), driving multiple compression; (4) the 16.8x forward P/E is contingent on consensus EPS that has been systematically wrong; and (5) technical structure is broken — death cross confirmed, price below all three MAs, MACD fresh negative crossover. While we acknowledge legitimate defensive characteristics ($7.2B FCF, 2.44% Dividend King yield, 0.586 beta), these provide a floor, not an upside catalyst. The plan's bull/bear asymmetry math (closer to 1:1 than the claimed 6:1 from $101.95) confirms no edge at current prices. We trim into the $100-103 resistance zone ahead of the binary September FOMC catalyst and Q3 earnings risk.

Stop loss: $99.50

Sizing: Reduce to below benchmark weight (~2-2.5% of healthcare allocation, or 30-50% reduction from current position levels). Do not add new exposure ahead of the September FOMC meeting.